NCT01303094 2026-03-16
T-DIS
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
36 trialsNCT04008238 2026-03-06
PIPER
Institut Bergonié
Phase NA Completed
NCT07444619 2026-03-03
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT04383119 2026-01-02
ISG-ARTICLE
Italian Sarcoma Group
Phase 2 Recruiting
NCT04076579 2025-08-29
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT06263231 2025-07-29
INVINCIBLE-3
Intensity Therapeutics, Inc.
Phase 3 Active not recruiting
NCT05597917 2025-04-04
TRABTRAP
Universität Münster
Phase 3 Recruiting
NCT03138161 2025-02-24
SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 1/2 Recruiting
NCT03886311 2025-02-24
TNT
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT04979442 2025-01-14
MANTRA
Rain Oncology Inc
Phase 3 Terminated
NCT02367924 2023-06-22
YonSar
PharmaMar, Spain
Completed
NCT02275286 2023-05-31
TRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Recruiting
NCT03985722 2023-03-27
OLATRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1 Unknown
NCT05131386 2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Unknown
NCT02359474 2023-02-28
HyperTET
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03590210 2022-11-08
NiTraSarc
University Medicine Greifswald
Phase 2 Completed
NCT02398058 2021-04-14
TOMAS
Italian Sarcoma Group
Phase 1 Completed
NCT02929394 2020-09-02
Trabectedin Maintenance Post 1st-line in STS
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT04394728 2020-05-19
Metabol-STS
Centro di Riferimento Oncologico - Aviano
Completed
NCT03397186 2019-09-10
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT02793050 2019-05-10
TrObs
Italian Sarcoma Group
Completed
NCT03496519 2018-10-09
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
University of Colorado, Denver
Phase 1 Withdrawn
NCT02672527 2018-08-16
TSAR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT01692678 2018-07-11
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Completed
NCT00379145 2017-12-12
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
GOG Foundation
Phase 2 Completed
NCT00210665 2017-10-10
A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
Janssen Research & Development, LLC
No longer available
NCT01453283 2017-07-02
Tabectedin to Treat Children and Adolescents With Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00796120 2015-12-10
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT01104298 2015-10-27
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Terminated
NCT01189253 2014-08-08
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Terminated
NCT00786838 2014-04-11
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00017030 2013-06-26
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005625 2013-06-19
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00102609 2013-01-10
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 1 Completed
NCT00003939 2012-09-24
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01427582 2011-09-01
YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
University of Texas Southwestern Medical Center
No longer available